# Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping

> **NCT04928690** · — · UNKNOWN · sponsor: **Novoic Limited** · enrollment: 140 (estimated)

## Conditions studied

- Alzheimer Disease
- Alzheimer's Disease (Incl Subtypes)
- Mild Cognitive Impairment

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04928690
- **Lead sponsor:** Novoic Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-20
- **Primary completion:** 2021-08-15
- **Final completion:** 2022-08-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04928690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04928690, "Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04928690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*